Vitrolife AB (publ) - Interim report January - June 2021: Good growth and acquisition of Igenomix
On July 15, 2021, Vitrolife reported impressive financial results for Q2 2021 with sales reaching SEK 382 million, an 83% increase. EBITDA rose to SEK 134 million (35% margin), while net income climbed to SEK 86 million (EPS of SEK 0.79). For H1 2021, sales were SEK 761 million, up 40%. The company announced the acquisition of Igenomix for EUR 1.25 billion (about SEK 12.7 billion), marking a strategic expansion.
- Sales increased by 83% in Q2 2021 to SEK 382 million.
- EBITDA reached SEK 134 million with a 35% margin.
- Net income for Q2 was SEK 86 million, with EPS of SEK 0.79.
- H1 2021 sales rose by 40% to SEK 761 million.
- Acquisition of Igenomix for EUR 1.25 billion indicates growth strategy.
- Currency effects negatively impacted Q2 EBITDA by SEK 15 million.
- Non-recurring costs from acquisitions and transport totaled SEK 14 million.
GOTHENBURG, Sweden, July 15, 2021 /PRNewswire/ -- Second quarter
- Sales amounted to SEK 382 (209) million, corresponding to an increase of 83 percent in SEK. Sales increased by 94 percent in local currency.
- Operating income before depreciation and amortisation (EBITDA) amounted to SEK 134 (40) million, corresponding to a margin of 35 (19) percent. Currency effects negatively impacted EBITDA by SEK 15 million. Operating income included non-recurring acquisition-related costs of SEK 11 million and non-recurring transport-related costs of SEK 3 million. Adjusted for these items, EBITDA amounted to SEK 148 million corresponding to a margin of 39 percent.
- Net income amounted to SEK 86 (12) million, which gave earnings per share of SEK 0.79 (0.11).
First half year
- Sales amounted to SEK 761 (543) million, corresponding to an increase of 40 percent in SEK. Sales increased by 49 percent in local currency.
- Operating income before depreciation and amortisation (EBITDA) amounted to SEK 297 (156) million, corresponding to a margin of 39 (29) percent. Currency effects negatively impacted EBITDA by SEK 25 million. Operating income included non-recurring acquisition-related costs of SEK 14 million and non-recurring transport-related costs of SEK 3 million. Adjusted for these items, EBITDA amounted to SEK 314 million, corresponding to a margin of 41 percent.
- Net income amounted to SEK 205 (92) million, which gave earnings per share of SEK 1.88 (0.84).
After the end of the period
- After closing day Vitrolife entered into an agreement to acquire
100% of the shares in Igenomix for a purchase sum of EUR 1.25 billion (approximately SEK 12.7 billion).
Gothenburg, July 15, 2021
VITROLIFE AB (publ)
Thomas Axelsson, CEO
This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on July 15, 2021 at 8.00 am CET.
CONTACT:
Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Interim report January - June 2021 |
View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-publ---interim-report-january--june-2021-good-growth-and-acquisition-of-igenomix-301334421.html
SOURCE Vitrolife AB (publ)
FAQ
What were Vitrolife's sales figures for Q2 2021?
What was the EBITDA margin for Vitrolife in Q2 2021?
What is the significance of Vitrolife's acquisition of Igenomix?
How did currency effects impact Vitrolife's financial results?
What was Vitrolife's net income and EPS for Q2 2021?
